Galectin-1 as an Emerging Mediator of Cardiovascular Inflammation: Mechanisms and Therapeutic Opportunities
| Autor: | Ignacio M. Seropian, Gabriel A. Rabinovich, Sebastian Matias Maller, Germán González, Antonio Abbate, Daniel Berrocal |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Vascular Endothelial Growth Factor A
0301 basic medicine CIENCIAS MÉDICAS Y DE LA SALUD Galectin 1 Angiogenesis Immunology Inflammation Review Article 030204 cardiovascular system & hematology T-Lymphocytes Regulatory Proinflammatory cytokine 03 medical and health sciences 0302 clinical medicine Mediator lcsh:Pathology medicine Animals Homeostasis Humans Myocardial infarction business.industry Patología purl.org/becyt/ford/3.1 [https] Cell Biology Cardiovascular disease medicine.disease Pulmonary hypertension Medicina Básica 030104 developmental biology Heart failure Galectin-1 purl.org/becyt/ford/3 [https] medicine.symptom business lcsh:RB1-214 |
| Zdroj: | Mediators of Inflammation Mediators of Inflammation, Vol 2018 (2018) CONICET Digital (CONICET) Consejo Nacional de Investigaciones Científicas y Técnicas instacron:CONICET |
| ISSN: | 1466-1861 0962-9351 |
| DOI: | 10.1155/2018/8696543 |
| Popis: | Galectin-1 (Gal-1), an evolutionarily conserved β-galactoside-binding lectin, controls immune cell homeostasis and tempers acute and chronic inflammation by blunting proinflammatory cytokine synthesis, engaging T-cell apoptotic programs, promoting expansion of T regulatory (Treg) cells, and deactivating antigen-presenting cells. In addition, this lectin promotes angiogenesis by co-opting the vascular endothelial growth factor receptor (VEGFR) 2 signaling pathway. Since a coordinated network of immunomodulatory and proangiogenic mediators controls cardiac homeostasis, this lectin has been proposed to play a key hierarchical role in cardiac pathophysiology via glycan-dependent regulation of inflammatory responses. Here, we discuss the emerging roles of Gal-1 in cardiovascular diseases including acute myocardial infarction, heart failure, Chagas cardiomyopathy, pulmonary hypertension, and ischemic stroke, highlighting underlying anti-inflammatory mechanisms and therapeutic opportunities. Whereas Gal-1 administration emerges as a potential novel treatment option in acute myocardial infarction and ischemic stroke, Gal-1 blockade may contribute to attenuate pulmonary arterial hypertension. Fil: Seropian, Ignacio Miguel. Hospital Italiano; Argentina Fil: González, Germán Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Bioquímica y Medicina Molecular. Universidad de Buenos Aires. Facultad Medicina. Instituto de Bioquímica y Medicina Molecular; Argentina Fil: Maller, Sebastian Matias. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Berrocal, Daniel H.. Hospital Italiano; Argentina Fil: Abbate, Antonio. Virginia Commonwealth University; Estados Unidos Fil: Rabinovich, Gabriel Adrián. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |